Pfizer Inc. (NYSE:PFE) today announced that it will be presenting data from 20 abstracts, including three late-breakers, at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen from October 7-11, 2016. The presentations demonstrate progress addressing cancer’s complex challenges through our work across 11 tumor types and eight distinct mechanisms of action, including two immuno-oncology/targeted therapy combination studies in renal cell carcinoma (RCC).
“Pfizer looks forward to sharing news from our diverse and growing oncology portfolio, particularly in the area of novel immunotherapies and combination approaches,” said Liz Barrett, global president and general manager, Pfizer Oncology. “We are also particularly pleased to present new data from our RCC franchise, where Pfizer has established itself as a leader in driving meaningful progress through significant contributions in RCC research and development.”
Pfizer will present data from three late-breaker abstracts at this year’s ESMO, including results from the S-TRAC clinical trial (Sunitinib Trial in Adjuvant Renal Cancer), a Phase 3 study of SUTENT® (sunitinib) versus placebo in the adjuvant setting, during a Presidential Symposium. Other late-breakers include early data from a Phase 1 study of PF-06647020, a novel antibody-drug conjugate (ADC) candidate targeting PTK7, a receptor tyrosine kinase associated with poorer prognosis that is expressed in many tumor types, and a biomarker analysis from the Phase 3 PALOMA-2 trial of IBRANCE® (palbociclib) in combination with letrozole in postmenopausal women with estrogen receptor-positive, human epidermal growth factor 2-negative (ER+/HER2–) metastatic breast cancer. These data for IBRANCE as well as health-related quality of life data from PALOMA-2 being presented as a poster discussion add to the growing body of evidence supporting the use of IBRANCE in this patient population.
Among six abstracts selected for poster discussion presentation at the meeting, four will address development efforts from Pfizer’s growing immuno-oncology pipeline. Highlights include data from two advanced RCC studies of INLYTA® (axitinib) in combination with different checkpoint inhibitors, including one study in combination with avelumab, an anti-PD-L1 IgG1 monoclonal antibody being developed through an Alliance between Pfizer and Merck KGaA, Darmstadt, Germany. Pfizer will also present the latest safety, anti-tumor activity and biomarker data from the first-in-human single-agent study of Pfizer’s investigational immunotherapy PF-04518600, an OX40 agonist, in a variety of advanced cancers. These preliminary results evaluating 25 patients suggest that PF-04518600 is tolerated up to 3 mg/kg and showed early anti-tumor activity.
Additionally, an updated data set from PROFILE 1001, a multicenter, single-arm Phase 1 study that examined use of XALKORI® (crizotinib) in patients with ROS1-positive advanced non-small cell lung cancer (NSCLC), will be presented. This analysis was used to support the recent approval of XALKORI in the European Union for patients with advanced NSCLC whose tumors are ROS1-positive.
Last updated on: 29/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.